Gene test could help smokers quit by matching them to the right drug
NCT ID NCT03227679
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a genetic biomarker called the Nicotine Metabolite Ratio (NMR) can help doctors choose the best FDA-approved smoking cessation medication for each person. 82 daily smokers were assigned to varenicline, bupropion, or nicotine patches based on their NMR result. The goal was to see if this personalized approach is feasible and acceptable to patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nicotine Metabolite Ratio (NMR) testing, varenicline, bupropion, nicotine patch
- What this could lead to
- If successful, this approach could help doctors personalize smoking cessation treatments, making them more effective for each individual.
- What could go wrong
- This is a small pilot study with only 82 participants, so results may not apply to everyone. It tested feasibility, not long-term quit rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOBACCO USE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized nicotine patch dosing may boost quit rates
- Talking it out: could a Conversation-Based approach curb smoking in future nurses?
- A stronger nicotine patch might break the dual Smoking-Vaping habit
- Could a child's doctor visit spark a parent's quit-smoking journey?
- A text at the right moment: can it defuse Stress-Led cravings?
- Which E-Cigarette designs are most addictive? a Head-to-Head test